Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Low p14ARF expression in neuroblastoma cells is associated with repressed histone mark status, and enforced expression induces growth arrest and apoptosis.
Dreidax D, Gogolin S, Schroeder C, Muth D, Brueckner LM, Hess EM, Zapatka M, Theißen J, Fischer M, Ehemann V, Schwab M, Savelyeva L, Westermann F. Dreidax D, et al. Among authors: theissen j. Hum Mol Genet. 2013 May 1;22(9):1735-45. doi: 10.1093/hmg/ddt020. Epub 2013 Jan 23. Hum Mol Genet. 2013. PMID: 23343716
MicroRNA miR-885-5p targets CDK2 and MCM5, activates p53 and inhibits proliferation and survival.
Afanasyeva EA, Mestdagh P, Kumps C, Vandesompele J, Ehemann V, Theissen J, Fischer M, Zapatka M, Brors B, Savelyeva L, Sagulenko V, Speleman F, Schwab M, Westermann F. Afanasyeva EA, et al. Among authors: theissen j. Cell Death Differ. 2011 Jun;18(6):974-84. doi: 10.1038/cdd.2010.164. Epub 2011 Jan 14. Cell Death Differ. 2011. PMID: 21233845 Free PMC article.
Telomerase activation by genomic rearrangements in high-risk neuroblastoma.
Peifer M, Hertwig F, Roels F, Dreidax D, Gartlgruber M, Menon R, Krämer A, Roncaioli JL, Sand F, Heuckmann JM, Ikram F, Schmidt R, Ackermann S, Engesser A, Kahlert Y, Vogel W, Altmüller J, Nürnberg P, Thierry-Mieg J, Thierry-Mieg D, Mariappan A, Heynck S, Mariotti E, Henrich KO, Gloeckner C, Bosco G, Leuschner I, Schweiger MR, Savelyeva L, Watkins SC, Shao C, Bell E, Höfer T, Achter V, Lang U, Theissen J, Volland R, Saadati M, Eggert A, de Wilde B, Berthold F, Peng Z, Zhao C, Shi L, Ortmann M, Büttner R, Perner S, Hero B, Schramm A, Schulte JH, Herrmann C, O'Sullivan RJ, Westermann F, Thomas RK, Fischer M. Peifer M, et al. Among authors: theissen j. Nature. 2015 Oct 29;526(7575):700-4. doi: 10.1038/nature14980. Epub 2015 Oct 14. Nature. 2015. PMID: 26466568 Free PMC article.
FOXP1 inhibits cell growth and attenuates tumorigenicity of neuroblastoma.
Ackermann S, Kocak H, Hero B, Ehemann V, Kahlert Y, Oberthuer A, Roels F, Theißen J, Odenthal M, Berthold F, Fischer M. Ackermann S, et al. Among authors: theissen j. BMC Cancer. 2014 Nov 18;14:840. doi: 10.1186/1471-2407-14-840. BMC Cancer. 2014. PMID: 25406647 Free PMC article.
Mutational dynamics between primary and relapse neuroblastomas.
Schramm A, Köster J, Assenov Y, Althoff K, Peifer M, Mahlow E, Odersky A, Beisser D, Ernst C, Henssen AG, Stephan H, Schröder C, Heukamp L, Engesser A, Kahlert Y, Theissen J, Hero B, Roels F, Altmüller J, Nürnberg P, Astrahantseff K, Gloeckner C, De Preter K, Plass C, Lee S, Lode HN, Henrich KO, Gartlgruber M, Speleman F, Schmezer P, Westermann F, Rahmann S, Fischer M, Eggert A, Schulte JH. Schramm A, et al. Among authors: theissen j. Nat Genet. 2015 Aug;47(8):872-7. doi: 10.1038/ng.3349. Epub 2015 Jun 29. Nat Genet. 2015. PMID: 26121086
A mechanistic classification of clinical phenotypes in neuroblastoma.
Ackermann S, Cartolano M, Hero B, Welte A, Kahlert Y, Roderwieser A, Bartenhagen C, Walter E, Gecht J, Kerschke L, Volland R, Menon R, Heuckmann JM, Gartlgruber M, Hartlieb S, Henrich KO, Okonechnikov K, Altmüller J, Nürnberg P, Lefever S, de Wilde B, Sand F, Ikram F, Rosswog C, Fischer J, Theissen J, Hertwig F, Singhi AD, Simon T, Vogel W, Perner S, Krug B, Schmidt M, Rahmann S, Achter V, Lang U, Vokuhl C, Ortmann M, Büttner R, Eggert A, Speleman F, O'Sullivan RJ, Thomas RK, Berthold F, Vandesompele J, Schramm A, Westermann F, Schulte JH, Peifer M, Fischer M. Ackermann S, et al. Among authors: theissen j. Science. 2018 Dec 7;362(6419):1165-1170. doi: 10.1126/science.aat6768. Science. 2018. PMID: 30523111 Free PMC article.
High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma.
Schulte JH, Bachmann HS, Brockmeyer B, Depreter K, Oberthür A, Ackermann S, Kahlert Y, Pajtler K, Theissen J, Westermann F, Vandesompele J, Speleman F, Berthold F, Eggert A, Brors B, Hero B, Schramm A, Fischer M. Schulte JH, et al. Among authors: theissen j. Clin Cancer Res. 2011 Aug 1;17(15):5082-92. doi: 10.1158/1078-0432.CCR-10-2809. Epub 2011 Jun 1. Clin Cancer Res. 2011. PMID: 21632861
Heterogeneity of the MYCN oncogene in neuroblastoma.
Theissen J, Boensch M, Spitz R, Betts D, Stegmaier S, Christiansen H, Niggli F, Schilling F, Schwab M, Simon T, Westermann F, Berthold F, Hero B. Theissen J, et al. Clin Cancer Res. 2009 Mar 15;15(6):2085-90. doi: 10.1158/1078-0432.CCR-08-1648. Epub 2009 Mar 10. Clin Cancer Res. 2009. PMID: 19276282
65 results